{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:28:48Z","timestamp":1792315728435,"version":"4.4.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ajp.2022.103051","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T11:39:22Z","timestamp":1645616362000},"page":"103051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical utility of trifluoperazine in the treatment of obsessive-compulsive disorder: A case report"],"prefix":"10.1016","volume":"71","author":[{"given":"Nellai K.","family":"Chithra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Suhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanteemar S.","family":"Sreeraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Venkatasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2022.103051_bib1","first-page":"18","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","author":"Dold","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2022.103051_bib2","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","article-title":"D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis","volume":"231","author":"Ducasse","year":"2014","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.ajp.2022.103051_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pbb.2017.12.006","article-title":"The antipsychotic trifluoperazine reduces marble-burying behavior in mice via D2 and 5-HT2A receptors: Implications for obsessive-compulsive disorder","volume":"165","author":"Egashira","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ajp.2022.103051_bib4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","article-title":"Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review","volume":"67","author":"Gao","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103051_bib5","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.4103\/0019-5545.196976","article-title":"Clinical practice guidelines for Obsessive-Compulsive Disorder","volume":"59","author":"Janardhan Reddy","year":"2017","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103051_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.MCT-16-0169-T","article-title":"Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R","volume":"16","author":"Kang","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ajp.2022.103051_bib7","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/S0024-3205(99)00203-9","article-title":"Nitric oxide synthase inhibitors enhance 5-HT2 receptor-mediated behavior, the head-twitch response in mice","volume":"64","author":"Kim","year":"1999","journal-title":"Life Sci."},{"key":"10.1016\/j.ajp.2022.103051_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103051_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2022.103051_bib10","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.4103\/psychiatry.IndianJPsychiatry_519_18","article-title":"Antipsychotic augmentation in the treatment of obsessive-compulsive disorder","volume":"61","author":"Thamby","year":"2019","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103051_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157232","article-title":"Calcium signaling pathway is associated with the long-term clinical response to selective serotonin reuptake inhibitors (SSRI) and SSRI with antipsychotics in patients with obsessive-compulsive disorder","volume":"11","author":"Umehara","year":"2016","journal-title":"PLOS One"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822000491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822000491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:42:04Z","timestamp":1761756124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201822000491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":11,"alternative-id":["S1876201822000491"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103051","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utility of trifluoperazine in the treatment of obsessive-compulsive disorder: A case report","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103051"}}